TOLMETIN is a Schedule H drug.


Canakinumab is a monoclonal antibody that blocks certain proteins in the body that can affect inflammation and other immune responses. This medication is an interleukin-1 beta-blocker, prescribed for auto-inflammatory diseases known as cryopyrin-associated periodic syndrome (CAPS). It decreases interleukin-1 beta’s activity. Canakinumab is used to treat certain types of periodic fever syndromes, sometimes called auto-inflammatory syndromes. It is also approved to treat systemic juvenile idiopathic arthritis (SJIA) in children two years and older.